CG
BTAI icon

Cutler Group’s BioXcel Therapeutics BTAI Stock Holding History

Cutler Group’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$8K Sell
188
-6
-3% -$286 ﹤0.01% 1361
2023
Q4 		$9K Sell
194
-194
-50% -$10.8K ﹤0.01% 2430
2023
Q3 		$15K Sell
388
-45
-10% -$4.55K ﹤0.01% 2214
2023
Q2 		$46K Buy
+433
New +$144K 0.01% 1333
2023
Q1 		– Sell
-54
Closed -$23.1K – 3845
2022
Q4 		$18K Sell
54
-125
-70% -$30.2K ﹤0.01% 2276
2022
Q3 		$33K Sell
179
-69
-28% -$16K ﹤0.01% 2213
2022
Q2 		$52K Buy
248
+154
+164% +$32.4K ﹤0.01% 1914
2022
Q1 		$31K Sell
94
-50
-35% -$14.5K ﹤0.01% 2661
2021
Q4 		$46K Sell
144
-37
-20% -$15.9K ﹤0.01% 2454
2021
Q3 		$88K Sell
181
-7
-4% -$3.08K ﹤0.01% 2023
2021
Q2 		$87K Sell
188
-15
-7% -$8.18K ﹤0.01% 1999
2021
Q1 		$139K Sell
203
-235
-54% -$189K 0.01% 1519
2020
Q4 		$323K Buy
438
+185
+73% +$144K 0.02% 838
2020
Q3 		$175K Sell
253
-360
-59% -$270K 0.01% 990
2020
Q2 		$519K Buy
613
+324
+112% +$211K 0.03% 482
2020
Q1 		$103K Buy
+289
New +$104K 0.01% 1310

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cutler Group's BTAI Position: Q1 2024 in Review

Cutler Group reduced its BioXcel Therapeutics (BTAI) stake by 3.1% in Q1 2024, selling an estimated $286 and leaving 188 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #1361.

Cutler Group first reported a position in BTAI in Q1 2020 and has held it in 16 quarters since. The position peaked at $519K in Q2 2020. 73 funds tracked by Wall St. Rank hold BTAI as of Q1 2024.

  • Cutler Group held 188 shares of BioXcel Therapeutics worth $8K as of Q1 2024.
  • Cutler Group sold 6 BioXcel Therapeutics shares in Q1 2024, an estimated $286.
  • BioXcel Therapeutics made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1361 holding.
  • Cutler Group first reported a position in BioXcel Therapeutics in Q1 2020 and has held it in 16 quarters since.
  • Cutler Group's BioXcel Therapeutics position peaked at $519K in Q2 2020.
  • 73 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.